Target intelligence / Profile preview

VSTM2B divergent transcript (VSTM2B-DT)

Target: VSTM2B-DT
Molecular classification: Other (Non-coding RNA; divergent transcript)

Overview

VSTM2B divergent transcript (VSTM2B-DT) is a long non-coding RNA annotated at the VSTM2B gene locus. It does not encode the V-Set and transmembrane domain containing 2B protein. There is no evidence to support its role as a therapeutic target, nor is it implicated in disease or clinical applications. It is listed in genomic data resources as a non-coding transcript, and its functional significance is currently unknown[3][4]. This designation appears to be an annotation artifact or minor variant at the locus, not a receptor, enzyme, transporter, nor drug target.

Other names: VSTM2B-DTVSTM2B divergent transcriptENSG00000264515

Biological functions

Other (Transcript; may be associated with regulation at the locus, but functions are unknown)

Beyond the preview

Go deeper on VSTM2B divergent transcript (VSTM2B-DT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VSTM2B divergent transcript (VSTM2B-DT).

Explore the full profile